NASDAQ: CYTH - Cyclo Therapeutics, Inc.

Altı ay boyunca karlılık: -50.58%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Cyclo Therapeutics, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

daha fazla ayrıntı
The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2011-02-23
ISIN US23254X2018
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://cyclotherapeutics.com
Цена ао 1.4
Günlük fiyat değişimi: +4.91% (0.57)
Haftalık fiyat değişimi: -5.08% (0.63)
Aylık fiyat değişimi: -16.94% (0.72)
3 ayda fiyat değişimi: -16.94% (0.72)
Altı ayda fiyat değişimi: -50.58% (1.21)
Yıllık fiyat değişimi: -62.39% (1.59)
3 yılda fiyat değişimi: -85.2% (4.04)
5 yılda fiyat değişimi: +99.33% (0.3)
10 yılda fiyat değişimi: 0% (0.598)
Yılbaşından bu yana fiyat değişimi: -14.45% (0.699)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 27 1
P/BV 6.11 1
P/E 0 0
EV/EBITDA -1.04 0
Toplam: 3.63

Yeterlik

İsim Anlam Seviye
ROA, % -151.4 0
ROE, % -421.64 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0516 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 7.64 1
karlılık Ebitda, % 178.21 10
karlılık EPS, % -80.53 0
Toplam: 6.2
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Founders Fund V Management, LLC 480708 1.67
Vanguard Group Inc 355223 1.24
Geode Capital Management, LLC 152077 0.53
Founders Fund VI Management, LLC 110023 0.38
Citadel Advisors Llc 54018 0.19
Blackrock Inc. 48444 0.17
State Street Corporation 39525 0.14
Wealth Enhancement Advisory Services, LLC 18513 0.06
Northern Trust Corporation 17453 0.06
XTX Topco Ltd 10696 0.04

ETF Paylaşmak, % Yıllık karlılık, % Temettüler, %
iShares Micro-Cap ETF 0.00344 17.09 1.54048



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. N. Scott Fine CEO & Director 569.92k 1957 (68 yıllar)
Mr. C. E Strattan Founder & Director N/A 1946 (79 yıllar)
Mr. Joshua M. Fine CFO & Secretary 421.17k 1982 (43 yıl)
Mr. Michael Eric Lisjak Senior VP of Business Development & Chief Regulatory Officer 430.4k 1974 (51 yıl)
Dr. Jeffrey L. Tate Ph.D. COO, Chief Quality Officer & Director 255.14k 1958 (67 yıllar)
Dr. Karen Mullen FFPM Interim Chief Medical Officer N/A
Ms. Lori McKenna Global Head of Patient Advocacy N/A

Adres: United States, Gainesville. FL, 6714 NW 16th Street - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://cyclotherapeutics.com